Chen J, Marechal V, Levine AJ
L., Fragala, M
Peptides for weight loss split into two very different categories: FDA-approved prescription GLP-1 drugs (semaglutide, tirzepatide, liraglutide) and non-prescription or compounded options (BPC-157, CJC-1295, AOD-9604, and similar peptides)
However, because of its severe side effects, which significantly reduce quality of life and affect treatment adherence, cisplatin has limited use in clinical practice (Pini et al., 2016
FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)
Vendors that require professional services for every configuration change become operational friction at scale